How advances in Illumina AI and informatics are driving research to make personalized cancer care more accessible

Innovations in AI and informatics are simplifying the complexity of next generation sequencing (NGS), making clinical research accessible to a wider range of labs and ushering in a new era of precision oncology.  

Join us to learn how the latest advances in Illumina software reduce time to report and increase confidence in clinical research with significantly more accurate, meaningful answers. 

New capabilities embedded in DRAGEN™ secondary analysis and Illumina Connected Insights for variant interpretation—including highly accurate oncogenicity prediction, prioritized variant review, and enhanced visualizations—help turn complex genomic data into clear, meaningful oncology insights you can trust. 

This webinar will feature the latest advances from Illumina informatics, including:

• Oncogenicity prediction scoring with significant accuracy improvements, powered by proprietary AI algorithms for more precise variant classification 
• Greater specificity in variant prioritization, streamlining interpretation by reducing the number of variants for review by up to 90%* 
• Push-button workflows and enhanced visualizations that can enable sophisticated applications such as comprehensive genomic profiling with TSO 500 v2, Minimal Residual Disease interrogation, and the first commercially available WGS hematopathology workflow 

Discover how informatics can propel your mission of personalized cancer forward, providing you with the latest innovations in analysis and interpretation to make NGS more approachable than ever.  

---

*As compared against Connected Insights Version 5.1. Illumina data on file, 2025.  

For Research Use Only. Not for use in diagnostic procedures.

M-GL-03717